Cardinal Point Capital Management ULC Buys Shares of 6,750 Merck & Co., Inc. $MRK

Cardinal Point Capital Management ULC bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,750 shares of the company’s stock, valued at approximately $534,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. 180 Wealth Advisors LLC lifted its stake in Merck & Co., Inc. by 14.4% in the second quarter. 180 Wealth Advisors LLC now owns 39,599 shares of the company’s stock valued at $3,135,000 after acquiring an additional 4,970 shares during the last quarter. Carnegie Investment Counsel lifted its stake in shares of Merck & Co., Inc. by 3.4% in the second quarter. Carnegie Investment Counsel now owns 65,524 shares of the company’s stock worth $5,187,000 after buying an additional 2,128 shares during the last quarter. Prentice Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 4.7% in the second quarter. Prentice Wealth Management LLC now owns 9,410 shares of the company’s stock worth $745,000 after buying an additional 425 shares during the last quarter. Strata Wealth Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter worth $231,000. Finally, FSM Wealth Advisors LLC raised its stake in Merck & Co., Inc. by 82.3% during the 2nd quarter. FSM Wealth Advisors LLC now owns 8,867 shares of the company’s stock valued at $717,000 after purchasing an additional 4,003 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 0.4%

Shares of NYSE MRK opened at $87.54 on Friday. The stock has a market cap of $218.65 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.96 and a beta of 0.37. The firm has a 50 day moving average price of $84.43 and a 200 day moving average price of $81.54. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $106.49.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MRK shares. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.